Literature DB >> 11409699

The phospholipase C-gamma1 gene (PLCG1) and lithium-responsive bipolar disorder: re-examination of an intronic dinucleotide repeat polymorphism.

R Løvlie1, J O Berle, E Stordal, V M Steen.   

Abstract

Twin, family and adoption studies have indicated that genetic susceptibility plays an important role in the etiology of bipolar disorder. Turecki et al. (1998) recently published preliminary evidence suggesting that bipolar patients with an excellent response to lithium treatment have a higher frequency of a specific dinucleotide repeat allele in the phospholipase Cgamma-1 (PLCG1) genomic region. The present work was undertaken to re-examine the finding by Turecki et al. in a sample of Norwegian lithium-treated bipolar patients sub-classified as lithium responders, non-responders, or partial responders/unclassified. The overall distribution of the PLCG1 dinucleotide repeat alleles was not significantly different between different categories of subjects. When analyzed according to presence or absence of different dinucleotide alleles, a PLCG1-8 repeat was more frequent among lithium responders vs controls. In line with Turecki et al., we also noticed a moderately over-representation of the PLCG1-5 repeat among the bipolar patients as compared to the controls.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11409699     DOI: 10.1097/00041444-200103000-00008

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.458


  15 in total

Review 1.  Genetics and psychopharmacology: prospects for individualized treatment.

Authors:  Charles U Nnadi; Joseph F Goldberg; Anil K Malhotra
Journal:  Essent Psychopharmacol       Date:  2005

Review 2.  The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine.

Authors:  Claudia Pisanu; Urs Heilbronner; Alessio Squassina
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

Review 3.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 4.  Pharmacogenetics of bipolar disorder.

Authors:  Hader A Mansour; Martin Alda; Vishwajit L Nimgaonkar
Journal:  Curr Psychiatry Rep       Date:  2002-04       Impact factor: 5.285

5.  Forebrain-specific ablation of phospholipase Cγ1 causes manic-like behavior.

Authors:  Y R Yang; J H Jung; S-J Kim; K Hamada; A Suzuki; H J Kim; J H Lee; O-B Kwon; Y K Lee; J Kim; E-K Kim; H-J Jang; D-S Kang; J-S Choi; C J Lee; J Marshall; H-Y Koh; C-J Kim; H Seok; S H Kim; J H Choi; Y-B Choi; L Cocco; S H Ryu; J-H Kim; P-G Suh
Journal:  Mol Psychiatry       Date:  2017-01-31       Impact factor: 15.992

6.  Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Authors:  Alessio Squassina; Mirko Manchia; Maria Del Zompo
Journal:  Hum Genomics Proteomics       Date:  2010-08-03

7.  Matrix metalloproteinase-9 gene and bipolar mood disorder.

Authors:  Janusz K Rybakowski; Maria Skibinska; Anna Leszczynska-Rodziewicz; Leszek Kaczmarek; Joanna Hauser
Journal:  Neuromolecular Med       Date:  2009-06-18       Impact factor: 3.843

8.  Genetic-linkage mapping of complex hereditary disorders to a whole-genome molecular-interaction network.

Authors:  Ivan Iossifov; Tian Zheng; Miron Baron; T Conrad Gilliam; Andrey Rzhetsky
Journal:  Genome Res       Date:  2008-04-16       Impact factor: 9.043

Review 9.  Long-term responsiveness to lithium as a pharmacogenetic outcome variable: treatment and etiologic implications.

Authors:  Firoza Mamdani; Iris Jaitovich Groisman; Martin Alda; Gustavo Turecki
Journal:  Curr Psychiatry Rep       Date:  2003-12       Impact factor: 5.285

10.  Regulation of neuronal PLCgamma by chronic morphine.

Authors:  Daniel H Wolf; Eric J Nestler; David S Russell
Journal:  Brain Res       Date:  2007-05-04       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.